Skip to main content
Top
Published in: Applied Health Economics and Health Policy 3/2011

01-05-2011 | Original Research Article

Hospital costs, length of stay and mortality associated with childhood, adolescent and young Adult meningococcal disease in the US

Authors: Keith L. Davis, Timothy J. Bell, Jacqueline M. Miller, Derek A. Misurski, Bela Bapat

Published in: Applied Health Economics and Health Policy | Issue 3/2011

Login to get access

Abstract

Background

Assessments of vaccination programmes should account for several important factors, including efficacy, safety and costs of preventing and treating the disease. Because patients with invasive meningococcal disease (IMD) are managed primarily in an inpatient setting, hospital costs and outcomes are central endpoints in health economic evaluations of IMD.

Objective

The aim of the study was to estimate hospital costs, length of stay (LOS) and mortality associated with IMD among children, adolescents and young adults in the US.

Methods

The study design was a retrospective analysis of discharges from the 2006 Healthcare Cost and Utilization Project Kids’ Inpatient Database. Infant (<1 year), childhood (1–10 years), adolescent (11–18 years) and young adult (19–20 years) IMD-related hospitalizations (International Classification of Diseases, Ninth Edition, Clinical Modification [ICD-9-CM] code 036) were selected. Regression-adjusted costs ($US, year 2009 values), LOS and mortality risk were compared between IMD hospitalizations and demographically matched (5:1) controls.

Results

A weighted total of 735 IMD admissions were identified. Among children, adjusted mean LOS and cost per admission was highest for infants (9.0 days and $US36454 among cases vs 1.9 days and $US5041 for controls; all p< 0.0001). Adjusted costs and case fatality was highest among infants with meningococcal sepsis ($US49 626 and 11.6%, respectively). Versus controls, adjusted risks of death in IMD cases were 4.6- and 10.3-fold higher, respectively, for infants and adolescents (both p < 0.05).

Conclusions

While the advent of vaccines for Haemophilus influenzae and Streptococcus pneumoniae has curtailed invasive bacterial infection rates, IMD continues to be a public health concern that presents greatly increased hospital costs, LOS and mortality risk, particularly for infants and adolescents.
Appendix
Available only for authorised users
Literature
1.
go back to reference Meredith JR, Galwankar S. Clinical and epidemiological implications of meningococcal disease. J Assoc Physicians India 2005; 53: 628–33 Meredith JR, Galwankar S. Clinical and epidemiological implications of meningococcal disease. J Assoc Physicians India 2005; 53: 628–33
2.
go back to reference Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344: 1378–88PubMedCrossRef Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344: 1378–88PubMedCrossRef
3.
go back to reference Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2005; 54(RR-07): 1–21 Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2005; 54(RR-07): 1–21
4.
go back to reference Centers for Disease Control and Prevention. Summary of notifiable diseases: United States. MMWR Morb Mortal Wkly Rep 2003; 52: 1–85 Centers for Disease Control and Prevention. Summary of notifiable diseases: United States. MMWR Morb Mortal Wkly Rep 2003; 52: 1–85
5.
go back to reference Rosenstein NE, Perkins BA. Update on Haemophilus influenzae serotype B and meningococcal vaccines. Pediatr Clin North Am 2000; 47: 337–52PubMedCrossRef Rosenstein NE, Perkins BA. Update on Haemophilus influenzae serotype B and meningococcal vaccines. Pediatr Clin North Am 2000; 47: 337–52PubMedCrossRef
6.
go back to reference Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50(2): 184–91PubMedCrossRef Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50(2): 184–91PubMedCrossRef
8.
go back to reference Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970–6PubMedCrossRef Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970–6PubMedCrossRef
9.
go back to reference Dawson KG, Emerson JC, Burns JL. Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J 1999; 18: 816–22PubMedCrossRef Dawson KG, Emerson JC, Burns JL. Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J 1999; 18: 816–22PubMedCrossRef
11.
go back to reference Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989–1991. MMWR CDC Surveill Summ 1993; 42(2): 21–30PubMed Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989–1991. MMWR CDC Surveill Summ 1993; 42(2): 21–30PubMed
12.
go back to reference Milonovich LM. Meningococcemia: epidemiology, pathophysiology, and management. J Pediatr Health Care 2007; 21(2): 75–80PubMedCrossRef Milonovich LM. Meningococcemia: epidemiology, pathophysiology, and management. J Pediatr Health Care 2007; 21(2): 75–80PubMedCrossRef
13.
go back to reference Black S, Shinefield HR, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumonococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187–95PubMedCrossRef Black S, Shinefield HR, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumonococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187–95PubMedCrossRef
14.
go back to reference Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000; 49(RR-9): 1–35 Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000; 49(RR-9): 1–35
16.
go back to reference Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10(5): 317–28PubMedCrossRef Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10(5): 317–28PubMedCrossRef
17.
go back to reference O’Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health 2006; 9(4): 236–42PubMedCrossRef O’Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health 2006; 9(4): 236–42PubMedCrossRef
18.
go back to reference Rancourt C, Grégoire JP, Simons W, et al. Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years. Pharmacoeconomics 2003; 21(6): 429–42PubMedCrossRef Rancourt C, Grégoire JP, Simons W, et al. Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years. Pharmacoeconomics 2003; 21(6): 429–42PubMedCrossRef
19.
go back to reference Davison KL, Ramsay ME, Crowcroft NS, et al. Estimating the burden of serogroup C meningococcal disease in England and Wales. Commun Dis Public Health 2002; 5(3): 213–9PubMed Davison KL, Ramsay ME, Crowcroft NS, et al. Estimating the burden of serogroup C meningococcal disease in England and Wales. Commun Dis Public Health 2002; 5(3): 213–9PubMed
20.
go back to reference Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 1974; 61: 439–47 Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 1974; 61: 439–47
21.
go back to reference Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461–94PubMedCrossRef Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461–94PubMedCrossRef
22.
go back to reference Manning WG. The logged dependent variable, hetero-scedasticity, and the retransformation problem. J Health Econ 1998; 17: 283–95PubMedCrossRef Manning WG. The logged dependent variable, hetero-scedasticity, and the retransformation problem. J Health Econ 1998; 17: 283–95PubMedCrossRef
23.
go back to reference Long JS. Regression models for categorical and limited dependent variables. Thousand Oaks (CA): Sage Publications, 1997 Long JS. Regression models for categorical and limited dependent variables. Thousand Oaks (CA): Sage Publications, 1997
24.
go back to reference Archer KJ, Lemeshow S, Hosmer DW. Goodness-of-fit tests for logistic regression models when data are collected using a complex sampling design. Comput Stat Data Analy 2007; 51(9): 4450–64CrossRef Archer KJ, Lemeshow S, Hosmer DW. Goodness-of-fit tests for logistic regression models when data are collected using a complex sampling design. Comput Stat Data Analy 2007; 51(9): 4450–64CrossRef
26.
go back to reference Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008; 46(1): 1–13PubMedCrossRef Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008; 46(1): 1–13PubMedCrossRef
27.
go back to reference O’Brien JA, Patrick AR, Caro JJ. Costs of managing CAP are double for elderly patients. Drug Benefit Trends 2003; 15: 32–47 O’Brien JA, Patrick AR, Caro JJ. Costs of managing CAP are double for elderly patients. Drug Benefit Trends 2003; 15: 32–47
28.
go back to reference Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010; 50: S45–53PubMedCrossRef Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010; 50: S45–53PubMedCrossRef
29.
go back to reference Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8(7): 851–61PubMedCrossRef Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8(7): 851–61PubMedCrossRef
30.
go back to reference Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197(5): 737–43PubMedCrossRef Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197(5): 737–43PubMedCrossRef
31.
go back to reference Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50: S37–44PubMedCrossRef Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50: S37–44PubMedCrossRef
Metadata
Title
Hospital costs, length of stay and mortality associated with childhood, adolescent and young Adult meningococcal disease in the US
Authors
Keith L. Davis
Timothy J. Bell
Jacqueline M. Miller
Derek A. Misurski
Bela Bapat
Publication date
01-05-2011
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 3/2011
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.2165/11587330-000000000-00000

Other articles of this Issue 3/2011

Applied Health Economics and Health Policy 3/2011 Go to the issue